11 COMMERCE DRIVE, CRANFORD, NJ
Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals Enters Third Amendment to Promissory Note
Ships First International Order of LYMPHIR™ to Europe
Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Elects Seven Directors at 2026 Annual Meeting
Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma
Q2
Q1
Amended Annual Report
FY 2025
Q3
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement